江苏华阳智能装备股份有限公司（以下简称"公司）于2024年12月13日召开 了第二届董事会第十四次会议，审议通过了《关于提请召开2024年第二次临时 股东大会的议案》，拟于2024年12月31日（星期二）召开公司2024年第二次临 时股东大会，现将会议有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2024年第二次临时股东大会。 证券代码：301502 证券简称：华阳智能 公告编号： 2024-037 江苏华阳智能装备股份有限公司 关于召开2024年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 2、股东大会召集人：公司董事会 3、会议召开的合法、合规性：本次临时股东大会的召开符合有关法律、行 政法规、部门规章、规范性文件、深圳证券交易所（以下简称"深交所"）业 务规则和公司章程等相关规定。 4、会议召开的日期、时间： 现场会议时间：2024年12月31日（星期二）下午14：00 网络投票时间：2024年12月31日（星期二） 其中，通过深圳证券交易所交易系统投票的时间为：2024年12月31日上午 9:15-9:25, ...

根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司独立董事管理办 法》（以下简称"《管理办法》"）《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作》（以下简称"《规范运作》"）等有关法律法规、规范性文件以及《江 苏华阳智能装备股份有限公司章程》（以下简称"《公司章程》"）的规定，我们作为公司第 二届董事会提名委员会的委员，对《关于公司董事会换届选举暨提名独立董事候选人的 议案》进行了认真的审阅，对独立董事候选人的任职条件和任职资格等相关材料进行了 审核，发表审查意见如下： 江苏华阳智能装备股份有限公司 第二届董事会提名委员会关于独立董事候选人 任职资格的审查意见 1、公司独立董事候选人干为民先生、史庆兰女士、周旭东先生具备《管理办法》《创 业板上市公司规范运作》规定的担任上市公司董事、独立董事的任职条件、任职资格，符 合相关法律法规规定的独立性等条件要求。 2、公司独立董事候选人干为民先生、史庆兰女士、周旭东先生的任职资格、教育背 景、工作经历、业务能力符合公司独立董事任职要求，不存在《公司法》《管理办法》《创 业板上市公司规范运作》等法律法规和《公司章程》中规定的不 ...

Group 1: Company Overview - Jiangsu Huayang Intelligent Equipment Co., Ltd. focuses on micro-special motors, primarily applied in refrigeration, with plans to expand into medical and other fields [2]. - The company established a wholly-owned subsidiary, Jiangsu Delphi Medical Devices Co., Ltd., to develop precision drug delivery devices like electronic injection pens [2]. Group 2: Market Insights - The domestic injection pen market is expected to grow due to increasing awareness of safe medication and the steady expansion of the downstream pharmaceutical market [3]. - The company has been in the injection pen industry for nearly 15 years, with a strong brand presence and extensive customer service experience [3]. Group 3: Product Differentiation - The electronic injection pen offers advantages such as precise dosage, adjustable speed, and the ability to record medication usage, distinguishing it from mechanical injection pens [3]. - Compared to foreign competitors, the company has lower development costs and faster customization capabilities, despite similar product functionality [3]. Group 4: Financial Performance - The decline in gross margin for injection pens this year is attributed to increased production of mechanical injection pens and slight price reductions [3]. - The company is actively tracking the demand for injection pens from large domestic and international pharmaceutical enterprises, aiming to expand into mature application markets [3].

Financial Performance - The company's revenue for Q3 2024 was ¥94,090,039, a decrease of 4.93% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was ¥4,759,282.24, down 66.14% year-on-year[2]. - The net profit after deducting non-recurring gains and losses was ¥2,972,313.27, a decline of 78.40% compared to the previous year[2]. - Total revenue for the third quarter reached ¥372,153,825.62, a slight increase of 0.22% compared to ¥366,364,251.19 in the same period last year[19]. - The net profit for Q3 2024 was CNY 25,203,970.09, a decrease of 47.5% compared to CNY 48,065,309.41 in Q3 2023[20]. - The total profit for Q3 2024 was CNY 27,005,614.91, down 50.1% from CNY 53,958,963.43 in the same period last year[20]. - Operating income for Q3 2024 was CNY 27,383,760.12, a decline of 48.9% compared to CNY 53,694,902.18 in Q3 2023[20]. - The company reported a decrease in sales revenue from CNY 198,108,258.08 in Q3 2023 to CNY 192,175,279.19 in Q3 2024, a decline of 3.9%[22]. Assets and Liabilities - Total assets at the end of Q3 2024 reached ¥1,041,317,068.82, an increase of 52.24% from the end of the previous year[2]. - The company's total liabilities increased to ¥223,800,292.27, up 7.88% from ¥208,029,322.11[17]. - Non-current assets totaled ¥346,563,281.94, up 20.14% from ¥288,467,454.72[17]. - Accounts receivable increased to ¥209,273,668.63, up 33.33% from ¥156,854,886.66 at the beginning of the period[16]. - Inventory levels rose to ¥111,204,277.91, an increase of 7.80% from ¥103,292,965.61[16]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 6,887[11]. - Jiangsu Huayang Investment Co., Ltd. holds 36.76% of shares, totaling 20,982,090 shares[11]. - Shanghai Fosun Chuangfu Investment Management Co., Ltd. holds 14.25% of shares, totaling 8,134,375 shares[11]. - Xu Yunchu, a natural person, holds 9.58% of shares, totaling 5,467,164 shares[11]. - Xu Mingfei, a natural person, holds 5.18% of shares, totaling 2,955,224 shares[11]. - The total number of restricted shares at the beginning of the period is 42,812,500, with 738,898 shares released during the period[14]. - The total number of unrestricted shares held by the top 10 shareholders is 42,812,500[14]. - The company has a significant shareholder relationship among the top shareholders, including family ties[12]. - The company has no changes in the number of restricted shares for major shareholders during the reporting period[14]. - The company plans to release restricted shares on specific future dates, with the earliest being February 2, 2025[14]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥23,509,602.30, a decrease of 50.66% compared to the same period last year[2]. - The company's cash and cash equivalents rose significantly to ¥95,831,025.93 from ¥21,204,331.68, marking an increase of 352.06%[16]. - Cash flow from operating activities for Q3 2024 was CNY 23,509,602.30, down 50.7% from CNY 47,647,966.02 in Q3 2023[22]. - Cash flow from investing activities showed a net outflow of CNY 270,889,979.29 in Q3 2024, compared to a net outflow of CNY 45,319,539.77 in Q3 2023[22]. - Cash flow from financing activities generated a net inflow of CNY 320,103,081.95 in Q3 2024, significantly higher than CNY 1,200,548.12 in Q3 2023[23]. - The company received CNY 373,106,983.87 in cash from financing activities in Q3 2024, compared to CNY 5,880,000.00 in Q3 2023[23]. Expenses - The company experienced a 50.40% increase in sales expenses, totaling ¥5,461,298.44, primarily due to higher advertising and travel costs[7]. - Total operating costs increased to ¥347,193,732.00, up 9.69% from ¥316,515,486.26 year-over-year[19]. - Research and development expenses were reported at ¥14,984,359.11, slightly down from ¥15,114,109.85 year-over-year[19]. Investment Income - Investment income surged by 586.72% to ¥346,116.35 due to increased financial investments[9].

证券代码：301502 证券简称：华阳智能 江苏华阳智能装备股份有限公司 投资者关系活动记录表 编号：2024-007 | --- | --- | --- | |-----------------------------|---------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2024, representing a 15% increase compared to the same period in 2023[7]. - The company has set a revenue target of RMB 1.2 billion for the full year 2024, which reflects a 10% growth from the previous year[7]. - The company's operating revenue for the reporting period was ¥278,063,786.62, representing a 3.99% increase compared to ¥267,399,733.40 in the same period last year[13]. - Net profit attributable to shareholders decreased by 39.94% to ¥20,436,142.62 from ¥34,026,036.01 year-on-year[13]. - The cash flow from operating activities dropped by 49.97% to ¥19,049,438.55 compared to ¥38,076,931.60 in the previous year[13]. - The gross profit margin for the first half of 2024 was reported at 35%, a slight decrease from 37% in the same period last year[7]. - The net profit attributable to shareholders for the first half of 2024 was ¥22,650,807.01, up from ¥18,364,492.84 in the first half of 2023, reflecting a growth of 23.5%[123]. - The total profit for the first half of 2024 was ¥23,789,525.57, compared to ¥20,461,837.50 in the same period of 2023, indicating an increase of 11.3%[122]. Market Expansion and Strategy - User data indicates a growth in active users by 20%, reaching 1.2 million users by the end of June 2024[7]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by the end of 2025[7]. - A strategic acquisition of a local competitor is in progress, which is anticipated to enhance the company's production capacity by 30%[7]. - The company is actively expanding its international market presence and has made breakthroughs in new sales channel construction[18]. - The company is expanding its micro-special motor and components business into new areas such as kitchen appliances and security monitoring, but has only achieved limited sales so far[55]. Research and Development - The company is investing RMB 50 million in research and development for new technologies in the next fiscal year[7]. - The company has developed a new gearbox component that enhances motor drive effectiveness and improves the smoothness of operations[18]. - The company is collaborating with multiple GLP-1 drug development firms to advance syringe projects, indicating a strong pipeline for future revenue[19]. - The company is diversifying its R&D efforts across various sectors, including home appliances and medical devices, to enhance growth potential and market adaptability[33]. - The company will continue to invest in research and development to enhance product competitiveness and develop proprietary technologies[76]. Financial Position and Assets - Total assets increased by 51.26% to ¥1,034,586,206.48 from ¥683,982,603.44 at the end of the previous year[13]. - Net assets attributable to shareholders rose by 70.69% to ¥812,131,964.60 from ¥475,802,407.26 year-on-year[13]. - The total liabilities at the end of the reporting period were 62,000,000.00 CNY, indicating a manageable debt level[135]. - The total equity at the end of the reporting period was 422,741,498.25 CNY, showing an increase from the previous year's total equity of 408,742,888.06 CNY[132]. Cash Flow and Financing - The company reported a significant increase in cash flow from financing activities, up 15,601.57% to 318,902.27 million yuan, attributed to IPO fundraising[37]. - The company raised ¥373,106,983.87 from financing activities in the first half of 2024, significantly higher than the ¥5,880,000.00 raised in the same period of 2023[125]. - Cash inflow from financing activities reached CNY 403,106,983.87, a substantial rise from CNY 5,880,000.00 in the same period last year[126]. Risk Management - The management highlighted potential risks including supply chain disruptions and regulatory changes, which could impact future performance[1]. - The company is addressing raw material price fluctuation risks by optimizing supply chain management and improving inventory turnover rates[55]. - The company plans to enhance its market research and responsiveness to industry policy changes to mitigate risks associated with policy impacts on sales[56]. Shareholder and Dividend Policy - The company will not distribute cash dividends for the fiscal year 2024, focusing instead on reinvestment for growth[1]. - The company plans to distribute cash dividends of no less than 10% of the distributable profits for the year, barring special circumstances[78]. - The company’s profit distribution policy is not to be changed arbitrarily and must comply with regulations from the China Securities Regulatory Commission[79]. Corporate Governance and Compliance - The company has established a multi-tier governance structure, including a shareholders' meeting, board of directors, and supervisory board[139]. - The company has committed to timely informing about business opportunities within its main business scope[83]. - The company has not reported any environmental penalties during the reporting period[63]. - The company emphasizes its core business philosophy of "Quality Achieves Development, Innovation Creates the Future" and actively fulfills social responsibilities[64]. Share Structure and IPO - The company completed its initial public offering (IPO) of 14,271,000 shares, increasing total shares from 42,812,500 to 57,083,500[100]. - The basic earnings per share (EPS) for 2023 is reported at 1.5265 CNY, which will be diluted to 1.0358 CNY post-share increase[100]. - The largest shareholder, Huayang Investment Co., Ltd., holds 36.76% of the shares, totaling 20,982,090 shares[105]. Product Development and Innovation - New product development includes the launch of a smart automation system, expected to contribute an additional RMB 100 million in revenue by Q4 2024[7]. - The precision drug delivery device segment is expected to accelerate its growth, with applications in various medications such as insulin and growth hormones, and ongoing collaborations with pharmaceutical companies for new product development[25][26]. - The company’s commitment to quality and innovation has led to a comprehensive product line in the precision drug delivery device sector, positioning it as a leader in the domestic market[26].

江苏华阳智能装备股份有限公司 关于2024年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》及《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 要求》等规定，将江苏华阳智能装备股份有限公司（以下简称"公司"或"华阳 智能"）2024年半年度募集资金存放与使用情况报告如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 证券代码：301502 证券简称：华阳智能 公告编号：2024-031 经中国证券监督管理委员会《关于同意江苏华阳智能装备股份有限公司首 次公开发行股票注册的批复》（证监许可〔2023〕2122 号）同意注册，并经深 圳证券交易所《关于江苏华阳智能装备股份有限公司人民币普通股股票在创业 板上市的通知》（深证上[2024]93 号）同意，公司首次公开发行人民币普通股 （A 股）股票 1,427.10 万股，每股面值为人民币 1.00 元，每股发行价格为人民 币 28.01 元，募集资金总额为人民币 3 ...

| 保荐机构名称：东吴证券股份有限公司 | 被保荐公司简称：华阳智能 | | --- | --- | | 保荐代表人姓名：徐欣 | 联系电话：0512-62938515 | | 保荐代表人姓名：黄萌 | 联系电话：0512-62938515 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0次 | | 2．督导公司建立健全并有效执行规章制度的 | | | 情况 | | | （1）是否督导公司建立健全规章制度（包括 | | | 但不限于防止关联方占用公司资源的制度、 | | | 募集资金管理制度、内控制度、内部审计制 | 是 | | 度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | | 保荐机构每月取得公司募集资金专户资金 | | （1）查询公司募集资金专户次数 | 变动情况和大额资金支取使用情况 | | （2）公司募集资金项目进展是否与信息披露 | 是 | | 文件一致 | | ...

江苏华阳智能装备股份有限公司 舆情管理制度 舆情管理制度 第一章 总则 第一条 为提高江苏华阳智能装备股份有限公司（以下简称"公司"）应对 各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对 公司股价、公司商业信誉及正常生产经营活动造成的影响，切实保护投资者合 法权益，根据相关法律、法规和规范性文件的规定及《公司章程》，结合公司 实际情况，制定本制度。 第二条 本制度所称"舆情"包括： （一）报刊、电视、网络等媒体对公司进行的负面或不实报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的 信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生 较大影响的事件信息。 第三条 舆情信息的分类： 江苏华阳智能装备股份有限公司 （一）决定启动和终止各类舆情处理工作的相关事宜； （二）评估各类舆情信息对公司可能造成的影响以及波及范围，拟定各类 舆情信息的处理方案； （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活 动，使公司已经或可能遭受损失，已经或可能造成公司股票及其衍生品种交易 价格变 ...

江苏华阳智能装备股份有限公司 第二届董事会第十二次会议决议公告 证券代码：301502 证券简称：华阳智能 公告编号：2024-029 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 江苏华阳智能装备股份有限公司（以下简称"公司"）第二届董事会第十二 次会议于 2024 年 8 月 16 日以电子邮件和电话方式发出会议通知，会议于 2024 年 8 月 27 日上午 9：30 以现场结合通讯的会议方式在公司会议室召开。会议应 出席董事 9 人，实际出席董事 9 人，公司监事、高级管理人员列席了会议。本次 会议由董事长许云初先生主持。会议的召集和召开符合《中华人民共和国公司法》 等法律法规和《公司章程》的有关规定。 二、董事会会议审议情况 与会董事对本次会议需审议的议案进行了充分讨论，审议通过了以下议案： 1、审议通过了《关于公司 2024 年半年度报告及其摘要的议案》 具体内容详见公司同日于巨潮资讯网（http://www.cninfo.com.cn）披露的 《2024 年半年度报告》及《2024 年半年度报告摘要》。 公司审计委员会已审议通 ...